nejm semaglutide cardiovascular SELECT Trial: 2.4 mg Cuts Risk in Obesity (NEJM 2023) Semaglutide in Patients with Heart

Glutathione, a potent antioxidant naturally produced in the body, has garnered attention for its potential health benefits

This cadence mirrors the follow-up structure used in chronic disease management and allows for safe, consistent prescription renewal without unnecessary visits

However, semaglutide may not be suitable for those with medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, pancreatitis, or severe gastrointestinal diseases, and these patients should explore alternate treatments with their provider

Top GLP-1 Telehealth Programs in 2025 Wondering which GLP-1 telehealth platforms to explore in 2025

What the evidence doesn't resolve is whether compounded GLP-1 preparations have equivalent efficacy and safety profiles to their brand-name FDA-approved counterparts